SCHEMBL7555908

SCHEMBL7555908

CCCCCc1cnc2sccc2c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.39
ALOX5 P09917 6/20 0.37
PTGS2 P35354 5/20 0.37
MAPT P10636 2/20 0.36
TP53 P04637 2/20 0.36
CYP3A4 P08684 2/20 0.36
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LIPG Q9Y5X9 1/20 0.34
ELANE P08246 2/20 0.34
CTSG P08311 2/20 0.34
NPC1 O15118 1/20 0.34
STAT3 P40763 1/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6529277 0.73 TLR7 (0.48) TYRALOX5PTGS2MAPTCYP3A4
SCHEMBL26936985 0.71 MRGPRX1 (0.41) MEN1HTTKMT2ANPC1RAB9A
SCHEMBL7850047 0.68 TLR7 (0.43) MAPTCYP3A4SMN1; SMN2ADORA3KDM4E
SCHEMBL10414775 0.67 TYR (0.49) TYRALOX5PTGS2MAPTTP53
SCHEMBL22120503 0.67 CHEK1 (0.40) MAPTMEN1KMT2ATDP1NPC1
SCHEMBL10741472 0.67 KMT2A (0.37) MAPTMEN1TSHRHTTKMT2A
SCHEMBL12098169 0.67 TYR (0.65) TYRALOX5PTGS2MAPTTP53
SCHEMBL7526376 0.66 HTT (0.46) MAPTMEN1TSHRHTTKMT2A
SCHEMBL25627152 0.66 CHEK1 (0.47) MAPTMEN1TSHRHTTKMT2A
SCHEMBL30916871 0.66 ALDH1A1 (0.47) MAPTTP53MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11130777-A None JP disclosed
US-20020198384-A1 Thienopyridine derivatives, their intermediates and production thereof MIKI SHOKYO (JP) 2002-12-26 US disclosed
US-6437132-B2 INHIBITOR OF GONADOTROPIN RELEASING HORMONE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-20 US disclosed
US-20020019529-A1 Thienopyridine derivatives, their intermediates and production thereof MIKI SHOKYO (JP) 2002-02-14 US disclosed
US-6313301-B1 CYCLIZATION; LUTEINIZING HORMONE RELEASING HORMONE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-11-06 US disclosed
EP-1004585-A1 THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH Takeda Chemical Industries, Ltd. (JP) 2000-05-31 EP disclosed
JP-H11130777-A THIENOPYRIDINE DERIVATIVE, ITS INTERMEDIATE AND THEIR PRODUCTION TAKEDA CHEM IND LTD 1999-05-18 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198384-A1 Thienopyridine derivatives, their intermediates and production thereof GNRHR, KISS1R, CYP19A1 TYR 737/4885ALOX5 1532/4885PTGS2 280/4885
US-20020019529-A1 Thienopyridine derivatives, their intermediates and production thereof GNRHR, KISS1R, CYP19A1 TYR 737/4885ALOX5 1532/4885PTGS2 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.